Loading…
Loading…
For investors seeking momentum, Alpha Blue Capital US Small-Mid Cap Dynamic ETF ABCS is probably on the radar now. The fund just hit a 52-week high and jumped 19.9% from its 52-week low price of $28.19 per share.
Alpha Blue Capital US Small Mid Cap Dynamic ETF (NASDAQ: ABCS - Get Free Report) was the target of a significant decrease in short interest in the month of December. As of December 31st, there was short interest totaling 710 shares, a decrease of 77.3% from the December 15th total of 3,127 shares. Approximately 0.2% of
Alpha Blue Capital US Small Mid Cap Dynamic ETF (NASDAQ: ABCS - Get Free Report) traded up 1.2% on Thursday. The stock traded as high as $31.09 and last traded at $31.09. 3,611 shares traded hands during trading, a decline of 1% from the average session volume of 3,631 shares. The stock had previously closed
Alpha Blue Capital US Small Mid Cap Dynamic ETF (NASDAQ: ABCS - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totaling 3,400 shares, an increase of 240.0% from the September 30th total of 1,000 shares. Based on an average daily volume of 3,400 shares,
Alpha Blue Capital US Small Mid Cap Dynamic ETF (NASDAQ: ABCS - Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totaling 3,400 shares, an increase of 240.0% from the September 30th total of 1,000 shares. Based on an average daily trading
The last full week of the year was a busy one, with 18 new ETFs launching. Among the rolled-out funds were offerings from Texas Capital, PlanRock, PGIM, John Hancock, SP Funds, Bancreek, KB Asset Management, ProShares, and WisdomTree.
WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)--Abacus Health Products, Inc. (CSE: ABCS, OTCQB: ABAHF) (“Abacus” or the “Company”) will release its 2019 fourth quarter and year-end financial results on Wednesday, April 29,2020, prior to the market open and management will host a conference call at 10:00 AM Eastern Time to review the financial results. Conference Call & Live Audio Webcast Details: All interested parties can join the conference call by dialing 1.844.260.4846 or 1.270.833.1296, conference ID: 8374589. Please dial-in or connect at least 15 minutes prior to the conference call to ensure a secure line. Archived Replay: For those parties unavailable to attend, the conference call will be archived for replay until May 6th, 2020. To access the archived conference call, please dial 1.855.859.2056 or 1.404.537.3406 and enter the conference ID 8374589. About Abacus Health Products, Inc. Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from Cannabis Sativa L. plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in an FDA registered and audited manufacturing facility. To learn more about Abacus, visit www.abacushp.com
WOONSOCKET, R.I. & TORONTO--(BUSINESS WIRE)--Abacus Health Products, Inc. (CSE: ABCS, OTCQX: ABAHF) (“Abacus” or the “Company”) will release its 2019 third quarter financial results on Thursday, November 21, 2019, prior to the market open and management will host a conference call at 10:00 AM Eastern Time to review the financial results. Conference Call & Live Audio Webcast Details: All interested parties can join the conference call by dialing 1.844.260.4846 or 1.270.833.1296, conference ID: 3343986. Please dial-in or connect at least 15 minutes prior to the conference call to ensure a secure line. Archived Replay: For those parties unavailable to attend, the conference call will be archived for replay until November 28th, 2019. To access the archived conference call, please dial 1.855.859.2056 or 1.404.537.3406 and enter the conference ID 3343986. About Abacus Health Products, Inc. Abacus is a company engaged in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and which contain organic and natural ingredients, including a cannabinoid-rich hemp extract containing CBD from Cannabis Sativa L. plant. Abacus’ products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary patent-pending technologies developed by Abacus. Abacus’ formulations combine advanced science with organic and natural ingredients to provide safe relief. Abacus currently offers two lines of products: (i) CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus’ products are offered across the United States and are produced by a contract manufacturer in a cGMP compliant and audited manufacturing facility. To learn more about Abacus, visit www.abacushp.com.
No recent filings indexed.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for ABCS and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.